Table 2. Preliminary NCI-60 One-Dose Cell Growth Percentages.
| growth
of selected cell lines (%) |
|||||||
|---|---|---|---|---|---|---|---|
| compound | mean GP (%) | SR | MOLT-4 | COLO 205 | TK-10 | SK-OV-3 | NCI/ADR-RES |
| 12 | 28.1 | 11.6 | 12.7 | 20.2 | 32.5 | 39.7 | –0.9 |
| 13 | 94.2 | 91.3 | 95.3 | 95.0 | 101.0 | 111.7 | 93.5 |
| 14 | 24.3 | 9.9 | 14.2 | 9.0 | 54.2 | 30.2 | 4.4 |
| 15 | 92.2 | 89.3 | 82.5 | 94.5 | 103.5 | 100.8 | 92.3 |
| 16 | 11.4 | 3.5 | 5.2 | 2.7 | 3.0 | 0.8 | 2.9 |
| 17 | 28.9 | 16.5 | 20.2 | 1.5 | 61.9 | 32.7 | 9.7 |
| 18 | 26.9 | 12.7 | 15.8 | 23.9 | 64.1 | 35.5 | –2.2 |
| 19 | 94.1 | 80.3 | 94.1 | 94.4 | 99.1 | 104.7 | 94.1 |
a
Cytotoxic data obtained from a preliminary NCI-60 screening assay. Mean GP represents the average cell growth of 60 cancer cell lines treated with compounds 12–19 at 10 μM concentration.